Uveitis News and Research

RSS
Uveitis is an inflammation of the uvea. The uvea is the front part of the eye. It includes the iris, which is the colored part of the eye, and the parts right next to and behind the iris. Uveitis may hurt a lot of parts of the eye. It may last as long as six weeks, or it may last a shorter time.
Scientists use AI to improve diagnosis and monitoring of rare eye condition

Scientists use AI to improve diagnosis and monitoring of rare eye condition

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

Microglia play vital role in regulating neuroinflammation, research shows

Microglia play vital role in regulating neuroinflammation, research shows

Ebola survivors in Liberia have higher prevalence of health issues, study shows

Ebola survivors in Liberia have higher prevalence of health issues, study shows

Researchers find a class of drug that could be promising treatment for uveitis

Researchers find a class of drug that could be promising treatment for uveitis

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Immunotherapy medicine found to be effective in treating uveitis

Immunotherapy medicine found to be effective in treating uveitis

Study reveals promising new drug candidate to treat acute renal failure

Study reveals promising new drug candidate to treat acute renal failure

Study: aPKC inhibitors may provide new therapeutic option for blinding eye diseases

Study: aPKC inhibitors may provide new therapeutic option for blinding eye diseases

New safety guideline released for prescribing biological therapies in inflammatory arthritis

New safety guideline released for prescribing biological therapies in inflammatory arthritis

Ocular Syphilis study finds increasing numbers of people at risk for permanent vision damage

Ocular Syphilis study finds increasing numbers of people at risk for permanent vision damage

UK’s leading sight loss charity invites applications from brightest minds in ophthalmic research

UK’s leading sight loss charity invites applications from brightest minds in ophthalmic research

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Fight for Sight partners with CSO to support vital sight-saving Scottish research

Fight for Sight partners with CSO to support vital sight-saving Scottish research

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients